This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Bulevirtide for treating chronic hepatitis D

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Bulevirtide for treating chronic hepatitis D

  • sodium taurocholate co-transporting polypeptide (NTCP) is the cell surface receptor for HBV and HDV entry into hepatocytes (1)
    • bulevirtide (BLV) interferes with the binding of NTCP and HBV/HDV
      • BLV is a large polypeptide mimics a region of the pre-S1 HBsAg and blocks viral entry by inhibitory competition
        • is a synthetic N-acylated pre-S1 lipopeptide that blocks the binding of HBsAg-enveloped particles to NTCP, which is the cell entry receptor for both HBV and HDV (2)
        • prevents the entry of HDV into hepatocytes, thereby decreasing the number of HDV-RNA templates needed for the synthesis of L- and S-HDAg
        • since there is no stable reservoir for HDV-RNA within infected hepatocytes, viral clearance might be achieved using antivirals for a minimum timeframe (1)
      • BLV is administered subcutaneously once daily at doses between 2 and 10 mg

NICE state:

  • bulevirtide is recommended as an option for treating chronic hepatitis D in adults with compensated liver disease only if:
    • there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and
    • their hepatitis has not responded to peginterferon alfa-2a (PEG-IFN) or they cannot have interferon-based therapy
    • bulevirtide is only recommended if the company provides it according to the commercial agreement
  • the NICE committee stated "..clinical trial evidence shows that bulevirtide is effective compared with standard care despite some uncertainties around how long it works for.."

Notes:

  • hepatitis D virus (HDV; Delta virus, family: Komlioviridae) depends on hepatitis B virus (HBV) envelope (HBV surface antigen, HBsAg) to form infectious HDV particle
    • HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC) (2)

Reference

  • Soriano V et al. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy. Drug Des Devel Ther. 2023 Jan 21;17:155-166. doi: 10.2147/DDDT.S379964. PMID: 36712949; PMCID: PMC9875571.
  • Ferenci P, Reiberger T, Jachs M. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update. Cells. 2022 Nov 8;11(22):3531. doi: 10.3390/cells11223531. PMID: 36428959; PMCID: PMC9688382.
  • NICE (June 2023). Bulevirtide for treating chronic hepatitis D

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.